Literature DB >> 6703206

Salivary gland tumors and previous radiotherapy to the head or neck. Report of a clinical series.

A D Katz, S Preston-Martin.   

Abstract

To estimate what proportion of patients with newly diagnosed salivary gland tumors may have radiation-related disease, we interviewed all 275 patients in a surgical practice who had salivary gland resections during an 8 year period. Patients were asked about previous radiation treatment to the head and neck. Thirty-one patients (11 percent) had both an incident salivary gland tumor and a history of significant exposure. Four of these patients (13 percent) had multiple primary tumors of the salivary glands. The implications and generalizability of these findings have been discussed herein.

Entities:  

Mesh:

Year:  1984        PMID: 6703206     DOI: 10.1016/0002-9610(84)90164-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Solid blue dot tumour: minor salivary gland acinic cell carcinoma.

Authors:  Radhika M Bavle; Soumya Makarla; Afreen Nadaf; Srinath Narasimhamurthy
Journal:  BMJ Case Rep       Date:  2014-06-13

2.  Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis.

Authors:  Houda Boukheris; Elaine Ron; Graça M Dores; Marilyn Stovall; Susan A Smith; Rochelle E Curtis
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

3.  Clinical approach and treatment of benign and malignant parotid masses, personal experience.

Authors:  F Bussu; C Parrilla; D Rizzo; G Almadori; G Paludetti; J Galli
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-06       Impact factor: 2.124

4.  Clinical history, prognostic factors, and management of facial nerve in malignant tumors of the parotid gland.

Authors:  Francesco Bussu; Mario Rigante; Veronica Giglia; Giovanni Bastanza; Eugenio De Corso; Giovanni Almadori; Gaetano Paludetti
Journal:  Clin Exp Otorhinolaryngol       Date:  2014-05-21       Impact factor: 3.372

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.